This article was originally published in The Gray Sheet
Laser developer's $30 mil. standby equity-based financing agreement with an institutional investor will help fund clinical trials of the IR-3000 laser system for presbyopia correction and rollout of the FDA-cleared EX308 laser for treatment of psoriasis. Resale of shares issued by the Orlando, Florida company under the agreement is expected to commence "in the early part of 2001," J.T. Lin, PhD, company president and CEO, remarked
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.